Physician profile
Parth Joshi
NPI 1689964355
$8,456.10
in general payments reported to CMS, 2019-2025
35 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $809 · 2021: $1,298 · 2022: $1,256 · 2023: $1,156 · 2024: $1,583 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,523.11 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,472.19 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $785.47 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $592.15 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $448.04 | 2019-2025 | |
| Celgene Corporation | $431.46 | 2021-2024 | Zeposia |
| Genzyme Corporation | $362.78 | 2022-2025 | |
| Pfizer INC. | $300.50 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $158.94 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $137.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $137.33 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $126.86 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $94.47 | 2021 | |
| Ironwood Pharmaceuticals, INC | $91.66 | 2019-2021 | |
| Vivus LLC | $74.96 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $64.72 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $62.73 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $49.65 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $49.47 | 2024 | Dupixent |
| Novo Nordisk INC | $48.65 | 2025 | Wegovy |
| Amgen INC. | $44.35 | 2024-2025 | Krystexxa, Uplizna |
| Ipsen Biopharmaceuticals, INC | $41.65 | 2024 | Iqirvo |
| Evoke Pharma, INC. | $40.51 | 2020-2022 | |
| Allergan, INC. | $39.14 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $38.54 | 2019-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $38.08 | 2020-2021 | |
| Lucid Diagnostics INC. | $37.75 | 2024 | |
| Exact Sciences Corporation | $37.70 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $21.28 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.16 | 2023 | Andexxa |
| Alnylam Pharmaceuticals INC. | $19.88 | 2023 | Givlaari |
| Braintree Laboratories, INC. | $18.75 | 2023 | Sutab, Suflave |
| Chiesi USA, INC. | $17.50 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.70 | 2021 | |
| Ucb, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.